Journal Article

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol

Budillon, Alfredo, Garcia Bermejo, Maria Laura, Milella, Michele, Hewitt, Eve, Leone, Alessandra, Silvestro, Lucrezia, Bruzzese, Francesca, Foschini, Francesca, Giannarelli, Diana, Fuchs, Claudia, Reni, Michele, Di Gennaro, Elena, Iannelli, Federica, Rodriguez Garrote, Mercedes, Roca, Maria Serena, Passaro, Eugenia, Avallone, Antonio, Macchini, Marina, Kubiak, Christine, Tortora, Giampaolo

2024

Overview

Background Metastatic pancreatic ductal adenocarcinoma (mPDAC) patients have very poor prognosis highlighting the urgent need of novel treatments. In this regard, repurposing non-oncology already-approved drugs might be an attractive strategy to offer more-effective treatment easily tested in clinical trials. Accumulating evidence suggests that epigenetic deregulation is a hallmark of cancer contributing to treatment resistance in several solid tumors, including PDAC. Histone deacetylase inhibitors (HDACi) are epigenetic drugs we have investigated preclinically and clinically as anticancer agents. Valproic acid (VPA) is a generic low-cost anticonvulsant and mood stabilizer with HDAC inhibitory activity, and anticancer properties also demonstrated in PDAC models. Statins use was reported to be associated with lower mortality risk in patients with pancreatic cancer and statins have been shown to have a direct antitumor effect when used alone or in combination therapy. We recently showed capability of VPA/Simvastatin (SIM) combination to potentiate the antitumor activity of gemcitabine/nab-paclitaxel in vitro and in vivo PDAC preclinical models. Methods/Design VESPA is a patient-centric open label randomized multicenter phase-II investigator-initiated trial, evaluating the feasibility, safety, and efficacy of VPA/SIM plus first line gemcitabine/nab-paclitaxel-based regimens (AG or PAXG) (experimental arm) versus chemotherapy alone (standard arm) in mPDAC patients. The study involves Italian and Spanish oncology centers and includes an initial 6-patients safety run-in-phase. A sample size of 240 patients (120 for each arm) was calculated under the hypothesis that the addition of VPA/SIM to gemcitabine and nab-paclitaxel-based regimens may extend progression free survival from 6 to 9 months in the experimental arm. Secondary endpoints are overall survival, response rate, disease control rate, duration of response, CA 19.9 reduction, toxicity, and quality of life. The study includes a patient engagement plan and complementary biomarkers studies on tumor and blood samples. Conclusions VESPA is the first trial evaluating efficacy and safety of two repurposed drugs in oncology such as VPA and SIM, in combination with standard chemotherapy, with the aim of improving mPDAC survival. The study is ongoing. Enrollment started in June 2023 and a total of 63 patients have been enrolled as of June 2024. Trial registration EudraCT number: 2022-004154-63; ClinicalTrials.gov identifier NCT05821556, posted 2023/04/20.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adenocarcinoma / Adult / Aged / Albumins - administration & dosage / Albumins - therapeutic use / Anticonvulsants / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Antineoplastic drugs / Antitumor activity / Apoptosis / Biomarkers / Biomedical and Life Sciences / Biomedicine / Cancer Research / Cancer therapies / Carcinoma, Pancreatic Ductal - drug therapy / Carcinoma, Pancreatic Ductal - pathology / Cell cycle / Chemotherapy / Cholesterol / Clinical trials / Deoxycytidine - administration & dosage / Deoxycytidine - analogs & derivatives / Deoxycytidine - therapeutic use / Disease control / Divalproex / Drug development / Drug Repositioning - methods / Drug repurposing / Drug resistance / Drug therapy / Drug therapy, Combination / Drugs / Epigenetics / FDA approval / Female / Gemcitabine / Gemcitabine, nab-paclitaxel / Gene expression / Health Promotion and Disease Prevention / Histone deacetylase / Humans / Male / Medical prognosis / Medicine/Public Health / Metabolism / Metabolites / Metastases / Metastasis / Middle Aged / Oncology / Paclitaxel / Paclitaxel - administration & dosage / Paclitaxel - therapeutic use / Pancreatic cancer / Pancreatic Neoplasms - drug therapy / Pancreatic Neoplasms - pathology / Patients / Pharmacokinetics / Quality of life / Simvastatin / Simvastatin - administration & dosage / Simvastatin - therapeutic use / Solid tumors / Statins / Study Protocol / Surgical Oncology / Survival / Testing / Toxicity / Treatment resistance / Tumors / Valproic acid / Valproic Acid - administration & dosage / Valproic Acid - therapeutic use